--- title: "Advancements in Mental Health Research: BICOMH 2026 Charts New Frontiers in Mood & Anxiety Care" slug: bicomh-2026-mood-anxiety-frontiers category: health category_label: "Health" author: "BrainWavePost Staff" date: 2026-07-16 tags: ["mental health", "BICOMH 2026", "mood disorders", "anxiety", "neuromodulation", "digital health"] read_time_minutes: 8 canonical_url: https://brainwavepost.com/article/bicomh-2026-mood-anxiety-frontiers source: BrainWavePost --- # Advancements in Mental Health Research: BICOMH 2026 Charts New Frontiers in Mood & Anxiety Care *Health · 2026-07-16 · BrainWavePost Staff · 8 min read* > The 2nd Biennial International Congress on Mental Health opened in Singapore this week, convening global experts around mood and anxiety disorders — with a programme focused on multimorbidity, digital innovation, neuromodulation and personalised therapies. > **How this article is sourced** _(info)_ > > Every claim below links to a primary or high-authority source: the Singapore Psychiatric Association's official BICOMH 2026 pages and Call for Abstracts, the WHO fact sheets on depression and anxiety disorders, and peer-reviewed 2026 reviews of neuromodulation for mood and anxiety. [1][2][3][4][5][6] The 2nd Biennial International Congress on Mental Health (BICOMH) 2026 opened on 15 July 2026 at One Farrer Hotel in Singapore, hosted by the Singapore Psychiatric Association. This year's theme — 'Scientific Frontiers in Mood & Anxiety Disorders: Multimorbidity, Digital Innovation, and Therapeutic Transformation' — sets the agenda for three days of sessions on how mood and anxiety conditions are understood, measured and treated. [1][2][3] The congress is being covered on the Mental Health Innovation Network, a WHO-linked platform, which describes the programme as reflecting 'both the foundations and the future' of mental health science — bringing together clinicians, researchers and digital-health developers around complex, co-occurring mood and anxiety presentations. [4] ## Why this congress matters Mood and anxiety disorders are the most common mental health conditions worldwide. WHO estimates that around 280 million people live with depression and 359 million with an anxiety disorder, yet roughly only 1 in 4 people with anxiety disorders receive treatment. [5][6] BICOMH 2026 is explicitly framed around closing that gap through better science and better tools. [3][4] - **~280M** — people living with depression worldwide (WHO)[5] - **359M** — people affected by anxiety disorders in 2021 (WHO)[6] - **~1 in 4** — adults with anxiety disorders who receive treatment (WHO)[6] ## The scientific programme, in plain English The official Call for Abstracts lists the congress's scientific tracks, which map closely to the themes highlighted by delegates on opening day. [3] - Transdiagnostic mental health and the multimorbidity of mood and anxiety disorders — recognising that depression, anxiety and other conditions frequently co-occur rather than appearing in isolation. [3] - Neurobiological and mechanistic research into mood and anxiety, including how brain circuits, stress and inflammation interact. [3] - Digital innovation in assessment and care — from validated digital screening to therapeutic apps and remote monitoring. [3][4] - Therapeutic transformation, spanning next-generation pharmacotherapy, neuromodulation and personalised (precision) psychiatry. [3][4] ## Neuromodulation moves further into the mainstream Neuromodulation — non-invasive brain stimulation techniques such as repetitive transcranial magnetic stimulation (rTMS) and intermittent theta-burst stimulation (iTBS) — is one of the congress's core threads. A 2026 systematic review in Brain Sciences examined iTBS for major depressive disorder with comorbid anxiety and found consistent reductions in both depressive and anxiety symptoms across the trials analysed, while also flagging predictors of response that could help match patients to treatment. [7] A separate 2026 systematic review in BMC Psychiatry evaluated TMS across generalised anxiety disorder, OCD and PTSD, concluding that TMS-based protocols show promising efficacy for anxiety-spectrum conditions but need larger, more standardised trials before becoming routine care. [8] A 2026 randomised controlled trial published in Frontiers in Neuroscience directly compared iTBS with sequential bilateral rTMS in major depressive disorder, reporting improvements in both depression severity and emotion-regulation measures. [9] > **What neuromodulation is — and isn't** _(note)_ > > Techniques like rTMS and iTBS use magnetic pulses to modulate activity in specific brain circuits without surgery or anaesthesia. They are approved in many countries for treatment-resistant depression, but they are not a first-line replacement for psychotherapy or medication, and access, cost and evidence still vary by indication. Any treatment decision should be made with a qualified clinician. [7][8][9] ## Digital innovation: from screening to therapy The programme's 'digital innovation' track reflects a broader shift in mental health care: validated digital tools are increasingly used alongside clinicians for screening, symptom tracking and structured therapy. The Mental Health Innovation Network summary of BICOMH 2026 highlights this integration of digital tools with traditional clinical pathways as central to the congress. [4] It builds on WHO's position that scaling access to effective care — including through appropriate digital channels — is essential to close the treatment gap in anxiety and depression. [5][6] ## Personalised, whole-person therapeutic approaches 'Therapeutic transformation' at BICOMH 2026 covers precision psychiatry: using clinical features, biomarkers and, increasingly, digital phenotyping data to match individuals to the therapies most likely to help them. That includes rethinking treatment-resistant depression — an area where Singapore's own Institute of Mental Health has recently expanded intravenous ketamine services for patients who have not responded to standard antidepressants, as reported by The Straits Times on the eve of the congress. [10] ## The takeaway BICOMH 2026's programme is a snapshot of where mainstream mood and anxiety research is heading: away from one-size-fits-all diagnoses and treatments, and toward integrated pathways that combine neurobiology, neuromodulation, digital tools and personalised care. The scale of the challenge — hundreds of millions of people affected, only a fraction in treatment — is exactly why the congress's cross-disciplinary framing matters. [3][4][5][6] > **Editorial note** _(tip)_ > > This article summarises publicly available congress materials and peer-reviewed research. It is not medical advice. If you're struggling with your mood or anxiety, please speak with a qualified mental health professional or a local support service. ## Sources and further reading - [1] Singapore Psychiatric Association — 'Biennial International Congress on Mental Health 2026' (event page): https://www.singaporepsychiatry.org.sg/bicomh-2026/ - [2] BICOMH 2026 — official congress site: https://www.bicomh.com/event/1db32e95-1acc-42fb-9f46-05fc4214ed5a/home - [3] Singapore Psychiatric Association — 'BICOMH 2026: Scientific Frontiers in Mood & Anxiety Disorders — Multimorbidity, Digital Innovation, and Therapeutic Transformation' (Call for Abstracts, PDF): https://www.singaporepsychiatry.org.sg/wp-content/uploads/BICOMH-2026_Call-for-Abstracts-v3.0.pdf - [4] Mental Health Innovation Network (WHO-linked) — 'Biennial International Congress on Mental Health 2026': https://www.mhinnovation.net/events/biennial-international-congress-mental-health-2026 - [5] World Health Organization — 'Depressive disorder (depression)' fact sheet: https://www.who.int/news-room/fact-sheets/detail/depression - [6] World Health Organization — 'Anxiety disorders' fact sheet: https://www.who.int/news-room/fact-sheets/detail/anxiety-disorders - [7] Brain Sciences (MDPI, 2026) — 'Intermittent Theta Burst Stimulation for Major Depressive Disorder with Comorbid Anxiety: A Systematic Review': https://www.mdpi.com/2076-3425/16/2/167 - [8] BMC Psychiatry (2026) — 'A systematic review of transcranial magnetic stimulation for generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder': https://link.springer.com/article/10.1186/s12888-026-07930-4 - [9] Frontiers in Neuroscience (2026) — 'Comparative effects of intermittent theta-burst stimulation and sequential bilateral rTMS on depression and emotion regulation in major depressive disorder: a randomized controlled trial': https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2026.1756383/full - [10] The Straits Times (14 July 2026) — 'Ketamine therapy at IMH offers hope to patients with hard-to-treat depression': https://www.straitstimes.com/singapore/health/ketamine-therapy-at-imh-offers-hope-to-patients-with-hard-to-treat-depression --- _Canonical article: [https://brainwavepost.com/article/bicomh-2026-mood-anxiety-frontiers](https://brainwavepost.com/article/bicomh-2026-mood-anxiety-frontiers) — © BrainWavePost. Educational content; see the article page for full disclaimers._